Charles River offers a wide range of neuroscience research products and services supported by our scientific depth, unique technical capabilities and experience in all the major neurodegenerative diseases and neurological indications, such as schizophrenia, Alzheimer’s disease, Parkinson’s disease, chronic pain, epilepsy, multiple sclerosis, stroke and ischemia. From animal models of disease to discovery research and preclinical testing, we have developed tools to assist clients in identifying the most promising candidate and shortening the development cycle of potential therapies with neurological implications.